Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France's Cellectis To Acquire Cellartis To Produce A Leader In Stem Cell Technologies

This article was originally published in The Pink Sheet Daily

Executive Summary

The genome engineering company, Cellectis, is to acquire the Swedish human embryonic stem cell firm Cellartis in a €30 million deal expected to complete at the end of October.
Advertisement

Related Content

Time To Strike On Regenerative Medicine/Stem Cell Companies?
Time To Strike On Regenerative Medicine/Stem Cell Companies?
France's Pharnext Attracts Business Leaders As Investors; Uses Network Pharmacology For New Low-Dose Combos
France's Pharnext Attracts Business Leaders As Investors; Uses Network Pharmacology For New Low-Dose Combos
Aastrom Moves Cell Therapy Into Phase III
AstraZeneca/Cellartis To Use Human Embryonic Stem Cells For Predictive Toxicology

Topics

Advertisement
UsernamePublicRestriction

Register

PS072778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel